Atorvastatin Therapy May Reduce the Incidence of Sudden Cardiac Death in Patients With Advanced Chronic Heart Failure

Journal of Cardiac Failure

Volumn 14, Issue 2, 2008, Pages 140-144

  Vrtovec, Bojan ^a   Okrajsek, Renata ^a   Golicnik, Alenka ^a   Ferjan, Mateja ^a   Starc, Vito ^b   Schlegel, Todd T ^c   Radovancevic, Branislav ^d  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c National Space Biomedical Research Institute   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

heart failure; statins; Sudden cardiac death

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE VARIABILITY; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSTHESIS FAILURE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; FEMALE; HEALTH STATUS INDICATORS; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; STROKE VOLUME;

EID: 39749111925     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.10.013     Document Type: Article

References (25)

1. Goldstein S. The changing epidemiology of sudden death in heart failure. Curr Heart Fail Rep 1 3 (2004) 93-97
2. Mark D.B., Nelson C.L., Anstrom K.J., Al-Khatib S.M., Tsiatis A.A., Cowper P.A., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114 2 (2006) 135-142
3. Cowie M.R., Mosterd A., Wood D.A., Deckers J.W., Poole-Wilson P.A., Sutton G.C., et al. The epidemiology of heart failure. Eur Heart J 18 2 (1997) 208-225
4. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296 17 (2006) 2105-2111
5. Vyas A.K., Guo H., Moss A.J., Olshansky B., McNitt S.A., Hall W.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 4 (2006) 769-773
6. Goldberger J.J., Subacius H., Schaechter A., Howard A., Berger R., Shalaby A., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 6 (2006) 1228-1233
7. Vrtovec B., Okrajsek R., Golicnik A., Ferjan M., Starc V., and Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11 9 (2005) 684-690
8. Vrtovec B., Starc V., and Starc R. Beat-to-beat QT interval variability in coronary patients. J Elecardiol 33 (2000) 119-125
9. Berger R.D., Kasper E.K., Baughman K.L., Marban E., Calkins H., and Tomaselli G.F. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 96 5 (1997) 1557-1565
10. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 93 (1996) 1043-1051
11. Stevenson W.G., Stevenson L.W., Middlekauff H.R., and Saxon L.A. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 88 6 (1993) 2953-2961
12. Akar F.G., and Rosenbaum D.S. Transmural electrophysiological heterogeneities underlying arrhythmogenesis in heart failure. Circ Res 93 7 (2003) 638-645
13. Antzelevitch C. Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis. Ann Med 36 Suppl 1 (2004) 5-14
14. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 8 (2004) 754-763
15. Starc V., and Schlegel T.T. Real-time multichannel system for beat-to-beat QT interval variability. J Electrocardiol 39 4 (2006) 358-367
16. Thomsen M.B., Oros A., Schoenmakers M., van Opstal J.M., Maas J.N., Beekman J.D., et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 73 3 (2007) 521-530
17. Haigney M.C., Zareba W., Gentlesk P.J., Goldstein R.E., Illovsky M., McNitt S., et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 44 (2004) 1481-1487
18. Atiga W.L., Calkins H., and Lawrence J.H. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 9 (1998) 899-908
19. Piccirillo G., Magri D., Matera S., Magnanti M., Torrini A., Pasquazzi E., et al. QT variability strongly predicts sudden cardiac death in asymptomatic subjects with mild or moderate left ventricular systolic dysfunction: a prospective study. Eur Heart J 28 11 (2007) 1344-1350
20. Pelat M., Dessy C., Massion P., Desager J.P., Feron O., and Balligand J.L. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 107 (2003) 2480-2486
21. Welzig C.M., Shin D.G., Park H.J., Kim Y.H., Saul J.P., and Galper J.B. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate. Circulation 108 (2003) 2743-2746
22. Yokoyama K., Ishibashi T., Ohkawara H., Kimura J., Matsuoka I., Sakamoto T., et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 105 (2002) 962-967
23. Zaca V., Rastogi S., Imai M., Wang M., Sharov V.G., Jiang A., et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50 6 (2007) 551-557
24. Petkova-Kirova P.S., Gursoy E., Mehdi H., McTiernan C.F., London B., and Salama G. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 290 5 (2006) H2098-H2107
25. Uretsky B.F., Thygesen K., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 6 (2000) 611-616